CD7 CAR-T Cells for Patients With R/R CD7+ NK/T Cell Lymphoma,T-lymphoblastic Lymphoma and Acute Lymphocytic Leukemia
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia. And to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.
T-lymphoblastic Lymphoma|NK/T Cell Lymphoma|Acute Lymphocytic Leukemia
DRUG: CD7 CAR-T cells infusion
Identification of the dose limiting toxicity (DLT), Toxicity will be assessed according to the NCI Common Terminology Criteria for Adverse Events (CTCAE) scale, version 5 and the number of patients experiencing DLT will be evaluated., Time Frame: 4 weeks after CAR T cell infusion
In vivo persistence/expansion of infused CAR T cell, Detection of infused CAR T cell in the peripheral blood., Up to 2 years|Determine the effects of CART-CD7 infusion on T cells and CD7 expression in vivo., Up to 2 years|Overall Response Rate (ORR), 4 weeks after CAR T cell infusion|Overall Survival, Up to 2 years|Disease-free survival, Up to 2 years
This study is designed to explore the safety and efficacy of CD7 CAR-T Cells for patients with relapse/refractory CD7+ NK/T cell lymphoma ,T-lymphoblastic lymphoma and Acute Lymphocytic Leukemia. And to evaluate the pharmacokinetics of CD7 CAR-T cells in patients.